NO20070176L - Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav - Google Patents

Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav

Info

Publication number
NO20070176L
NO20070176L NO20070176A NO20070176A NO20070176L NO 20070176 L NO20070176 L NO 20070176L NO 20070176 A NO20070176 A NO 20070176A NO 20070176 A NO20070176 A NO 20070176A NO 20070176 L NO20070176 L NO 20070176L
Authority
NO
Norway
Prior art keywords
pyrazoles
compounds
drugs containing
glycoside derivatives
new fluorine
Prior art date
Application number
NO20070176A
Other languages
English (en)
Norwegian (no)
Inventor
Heiner Glombik
Hubert Heuer
Martin Bickel
Wendelin Frick
Harm Brummerhop
Oliver Plettenburg
Stefan Theis
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20070176L publication Critical patent/NO20070176L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
NO20070176A 2004-06-11 2007-01-10 Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav NO20070176L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004028241A DE102004028241B4 (de) 2004-06-11 2004-06-11 Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
PCT/EP2005/005959 WO2005121161A1 (de) 2004-06-11 2005-06-03 Neue fluorglykosidderivate von pyrazolen, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
NO20070176L true NO20070176L (no) 2007-03-09

Family

ID=35355753

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070176A NO20070176L (no) 2004-06-11 2007-01-10 Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav

Country Status (33)

Country Link
US (1) US7820804B2 (pt)
EP (1) EP1758914B1 (pt)
JP (1) JP4996464B2 (pt)
CN (1) CN100582116C (pt)
AR (1) AR049393A1 (pt)
AU (1) AU2005252329B2 (pt)
BR (1) BRPI0510770A (pt)
CA (1) CA2570042C (pt)
CR (1) CR8773A (pt)
CY (1) CY1107426T1 (pt)
DE (2) DE102004028241B4 (pt)
DK (1) DK1758914T3 (pt)
EC (1) ECSP067054A (pt)
ES (1) ES2296180T3 (pt)
HR (1) HRP20080023T3 (pt)
IL (1) IL179757A (pt)
MA (1) MA28653B1 (pt)
MX (1) MXPA06013513A (pt)
MY (1) MY143565A (pt)
NO (1) NO20070176L (pt)
NZ (1) NZ551948A (pt)
PE (1) PE20060297A1 (pt)
PL (1) PL1758914T3 (pt)
PT (1) PT1758914E (pt)
RS (1) RS50541B (pt)
RU (1) RU2370499C2 (pt)
SI (1) SI1758914T1 (pt)
TN (1) TNSN06409A1 (pt)
TW (1) TWI382030B (pt)
UA (1) UA89787C2 (pt)
UY (1) UY28955A1 (pt)
WO (1) WO2005121161A1 (pt)
ZA (1) ZA200608832B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2076503B1 (en) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
US8115017B2 (en) * 2006-06-29 2012-02-14 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
DE102006053637B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5272395B2 (ja) * 2007-12-12 2013-08-28 セントラル硝子株式会社 ４−デオキシ−４−フルオロ−ｄ−グルコース誘導体の製造方法
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075582A1 (es) 2009-02-23 2011-04-20 Taisho Pharmaceutical Co Ltd Compuestos de 4- isopropilfenilglucitol
KR20120060207A (ko) * 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2298782A1 (en) * 2009-08-26 2011-03-23 Sanofi-Aventis Method for producing pyrazole glycoside derivatives
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
EP2498759B1 (en) 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
WO2011060255A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2607360B1 (en) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. 4-Isopropyl-6-methoxyphenyl glucitol compound
TW201219414A (en) 2010-08-20 2012-05-16 Taisho Pharmaceutical Co Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
MY176162A (en) 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
EP3778593A4 (en) * 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT850948E (pt) * 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
KR100591585B1 (ko) * 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
ES2337127T3 (es) * 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
AU2002240336A1 (en) * 2001-02-14 2002-08-28 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
RU2356906C2 (ru) * 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) * 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
US7576063B2 (en) * 2002-10-04 2009-08-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US20060035844A1 (en) * 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2529878C (en) * 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor

Also Published As

Publication number Publication date
CY1107426T1 (el) 2012-12-19
CA2570042C (en) 2013-01-15
JP2008501745A (ja) 2008-01-24
ECSP067054A (es) 2007-01-26
WO2005121161A1 (de) 2005-12-22
DE502005002056D1 (de) 2008-01-03
UY28955A1 (es) 2006-01-31
RU2007101154A (ru) 2008-07-20
MA28653B1 (fr) 2007-06-01
EP1758914A1 (de) 2007-03-07
MXPA06013513A (es) 2007-03-01
DE102004028241A1 (de) 2006-01-05
TW200610527A (en) 2006-04-01
CA2570042A1 (en) 2005-12-22
IL179757A (en) 2010-12-30
BRPI0510770A (pt) 2007-11-20
IL179757A0 (en) 2007-05-15
DE102004028241B4 (de) 2007-09-13
UA89787C2 (ru) 2010-03-10
PT1758914E (pt) 2008-01-31
EP1758914B1 (de) 2007-11-21
NZ551948A (en) 2010-04-30
JP4996464B2 (ja) 2012-08-08
MY143565A (en) 2011-05-31
CR8773A (es) 2008-02-28
RS50541B (sr) 2010-05-07
ZA200608832B (en) 2008-05-28
PL1758914T3 (pl) 2008-04-30
CN100582116C (zh) 2010-01-20
US7820804B2 (en) 2010-10-26
AU2005252329B2 (en) 2011-02-10
SI1758914T1 (sl) 2008-04-30
HRP20080023T3 (en) 2008-06-30
AU2005252329A1 (en) 2005-12-22
PE20060297A1 (es) 2006-05-25
US20070197623A1 (en) 2007-08-23
CN1964984A (zh) 2007-05-16
TNSN06409A1 (en) 2008-02-22
TWI382030B (zh) 2013-01-11
DK1758914T3 (da) 2008-03-17
RU2370499C2 (ru) 2009-10-20
ES2296180T3 (es) 2008-04-16
HK1100411A1 (zh) 2007-09-21
AR049393A1 (es) 2006-07-26

Similar Documents

Publication Publication Date Title
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20050649L (no) Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20066055L (no) Pyridinderivater
NO20053201L (no) Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse.
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20074872L (no) Pyrazoler
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
NO20055977L (no) Nye benzimidazolderivater
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
WO2007036532A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application